Report Detail

Pharmaceuticals & Healthcare Macular Edema - Pipeline Review, H1 2018

  • RnM2135019
  • |
  • 22 July, 2020
  • |
  • Global
  • |
  • 92 Pages
  • |
  • Global Markets Direct
  • |
  • Pharmaceuticals & Healthcare

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Macular Edema - Overview

              Macular Edema - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Products under Development by Companies

                      Macular Edema - Therapeutics Assessment

                        Assessment by Target

                          Assessment by Mechanism of Action

                            Assessment by Route of Administration

                              Assessment by Molecule Type

                                Macular Edema - Companies Involved in Therapeutics Development

                                  Anew Oncology Inc

                                    AsclepiX Therapeutics Inc

                                      Celon Pharma SA

                                        Clearside BioMedical Inc

                                          Coherus BioSciences Inc

                                            F. Hoffmann-La Roche Ltd

                                              Formycon AG

                                                Lupin Ltd

                                                  Luye Pharma Group Ltd

                                                    Mabion SA

                                                      OMEICOS Therapeutics GmbH

                                                        PharmAbcine Inc

                                                          Polus Inc

                                                            Profarma

                                                              Sustained Nano Systems LLC

                                                                Taiwan Liposome Co Ltd

                                                                  Targeted Therapy Technologies LLC

                                                                    Tarsius Pharma Ltd

                                                                      Xbrane Biopharma AB

                                                                        Macular Edema - Drug Profiles

                                                                          ACX-107 - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  aflibercept biosimilar - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          aflibercept biosimilar - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  aflibercept biosimilar - Drug Profile

                                                                                                    Product Description

                                                                                                      Mechanism Of Action

                                                                                                        R&D Progress

                                                                                                          aflibercept biosimilar - Drug Profile

                                                                                                            Product Description

                                                                                                              Mechanism Of Action

                                                                                                                R&D Progress

                                                                                                                  aflibercept biosimilar - Drug Profile

                                                                                                                    Product Description

                                                                                                                      Mechanism Of Action

                                                                                                                        R&D Progress

                                                                                                                          bevacizumab biosimilar - Drug Profile

                                                                                                                            Product Description

                                                                                                                              Mechanism Of Action

                                                                                                                                R&D Progress

                                                                                                                                  Macular Edema - Dormant Projects

                                                                                                                                    Macular Edema - Discontinued Products

                                                                                                                                      Macular Edema - Product Development Milestones

                                                                                                                                        Featured News & Press Releases

                                                                                                                                          Apr 28, 2020: Clearside Biomedical revises NDA resubmission timeline and XIPERE commercial partnership with Bausch Health

                                                                                                                                            Jan 28, 2020: Bausch Health and Clearside Biomedical announce publication of PIVOTAL phase 3 data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology

                                                                                                                                              Aug 22, 2019: Clearside Biomedical provides new drug application update for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension)

                                                                                                                                                Jul 31, 2019: Clearside Biomedical announces multiple oral presentations delivered at the American Society of Retinal Specialists (ASRS) Annual Meeting

                                                                                                                                                  May 01, 2019: Clearside Biomedical presents on Triamcinolone at the American Uveitis Society Spring Meeting 2019

                                                                                                                                                    Apr 18, 2019: Clearside Biomedical announces presentations on its Suprachoroidal Space injection platform with Triamcinolone Acetonide at upcoming medical meetings

                                                                                                                                                      Feb 20, 2019: Clearside Biomedical receives notification of FDA acceptance of NDA filing for XIPERE (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection with PDUFA Date Set for October 19, 2019

                                                                                                                                                        Jan 20, 2019: Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE Exhibits Durability Following Second Dose

                                                                                                                                                          Dec 19, 2018: Clearside Biomedical submits New Drug Application for XIPERE for the treatment of Macular Edema associated with Uveitis

                                                                                                                                                            Oct 29, 2018: Presentation of additional analyses of Clearsides PEACHTREE clinical trial data further supports potential of XIPERE in treating uveitic macular edema

                                                                                                                                                              Oct 22, 2018: CLEARSIDE, XIPERE and PEACHTREE to be front and center at AAO 2018

                                                                                                                                                                Sep 18, 2018: Positive PEACHTREE Data to be Highlighted at EURETINA 2018

                                                                                                                                                                  Sep 13, 2018: Data from Clearside Biomedical’s pivotal phase 3 PEACHTREE clinical trial in macular edema associated with non-infectious uveitis to be presented at the Retina Society 51st Annual Scientific Meeting

                                                                                                                                                                    Sep 12, 2018: Single suprachoroidal steroid injection boosts visual acuity in patients with macular edema

                                                                                                                                                                      Jul 16, 2018: Clearside Biomedical to Present Data from its Pivotal Phase 3 (PEACHTREE) Trial in Macular Edema Associated with Uveitis at the 2018 American Society of Retina Specialists Annual Meeting

                                                                                                                                                                        Appendix

                                                                                                                                                                          Methodology

                                                                                                                                                                            Coverage

                                                                                                                                                                              Secondary Research

                                                                                                                                                                                Primary Research

                                                                                                                                                                                  Expert Panel Validation

                                                                                                                                                                                    Contact Us

                                                                                                                                                                                      Disclaimer

                                                                                                                                                                                      Macular Edema - Pipeline Review, H1 2020

                                                                                                                                                                                      Summary

                                                                                                                                                                                      Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H1 2020, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

                                                                                                                                                                                      Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

                                                                                                                                                                                      Report Highlights

                                                                                                                                                                                      Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                                                                                                                                                                                      The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 1, 1, 2, 11, 1 and 1 respectively.

                                                                                                                                                                                      Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

                                                                                                                                                                                      Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                                                                      Scope

                                                                                                                                                                                      - The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
                                                                                                                                                                                      - The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
                                                                                                                                                                                      - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
                                                                                                                                                                                      - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
                                                                                                                                                                                      - The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
                                                                                                                                                                                      - The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
                                                                                                                                                                                      - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
                                                                                                                                                                                      - The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

                                                                                                                                                                                      Reasons to Buy

                                                                                                                                                                                      - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
                                                                                                                                                                                      - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
                                                                                                                                                                                      - Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
                                                                                                                                                                                      - Classify potential new clients or partners in the target demographic.
                                                                                                                                                                                      - Develop tactical initiatives by understanding the focus areas of leading companies.
                                                                                                                                                                                      - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
                                                                                                                                                                                      - Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
                                                                                                                                                                                      - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
                                                                                                                                                                                      - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


                                                                                                                                                                                      Summary:
                                                                                                                                                                                      Get latest Market Research Reports on Macular Edema. Industry analysis & Market Report on Macular Edema is a syndicated market report, published as Macular Edema - Pipeline Review, H1 2018. It is complete Research Study and Industry Analysis of Macular Edema market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                                                      Last updated on

                                                                                                                                                                                      REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                      Purchase this Report

                                                                                                                                                                                      $2,000.00
                                                                                                                                                                                      $4,000.00
                                                                                                                                                                                      $6,000.00
                                                                                                                                                                                      1,498.36
                                                                                                                                                                                      2,996.72
                                                                                                                                                                                      4,495.07
                                                                                                                                                                                      1,685.56
                                                                                                                                                                                      3,371.12
                                                                                                                                                                                      5,056.69
                                                                                                                                                                                      208,018.00
                                                                                                                                                                                      416,036.00
                                                                                                                                                                                      624,054.00
                                                                                                                                                                                      148,193.60
                                                                                                                                                                                      296,387.20
                                                                                                                                                                                      444,580.80
                                                                                                                                                                                      Credit card Logo

                                                                                                                                                                                      Related Reports


                                                                                                                                                                                      Reason to Buy

                                                                                                                                                                                      Request for Sample of this report